Five Years of Sacubitril/Valsartan—a Safety Analysis of Randomized Clinical Trials and Real-World Pharmacovigilance

被引：0
|
作者：
Yee Soo Kim
Simerjeet Brar
Natalie D’Albo
Amit Dey
Sachin Shah
Sarju Ganatra
Sourbha S. Dani
机构：
[1] Lahey Hospital and Medical Center,Department of Internal Medicine
[2] Georgetown University Medical Center,Department of Internal Medicine
[3] Lahey Hospital and Medical Center,Beth Israel Lahey Health, Department of Cardiovascular Medicine
来源：
Cardiovascular Drugs and Therapy | 2022年 / 36卷
关键词：
Sacubitril/valsartan; FDA Adverse Event Reporting System; Real-world pharmacovigilance; Disproportionality analysis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：915 / 924
页数：9
相关论文
共 50 条
  • [1] Five Years of Sacubitril/Valsartan-a Safety Analysis of Randomized Clinical Trials and Real-World Pharmacovigilance
    Kim, Yee Soo
    Brar, Simerjeet
    D'Albo, Natalie
    Dey, Amit
    Shah, Sachin
    Ganatra, Sarju
    Dani, Sourbha S.
    CARDIOVASCULAR DRUGS AND THERAPY, 2022, 36 (05) : 915 - 924
  • [2] FIVE-YEAR SAFETY ANALYSIS OF SACUBITRIL/VALSARTAN: A COMPARATIVE ANALYSIS OF ADVERSE EVENTS IN RANDOMIZED CLINICAL TRIALS AND REAL-WORLD PHARMACOVIGILANCE
    Kim, Yee Soo
    Brar, Simerjeet
    D'Albo, Natalie
    Shah, Sachin
    Ganatra, Sarju
    Dani, Sourbha
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2021, 77 (18) : 663 - 663
  • [3] Five years of safety profile of bevacizumab: an analysis of real-world pharmacovigilance and randomized clinical trials
    Wang, Li
    Fei, Yibo
    Qu, Han
    Zhang, Haiyang
    Wang, Yuanyuan
    Wu, Zhenghua
    Fan, Guorong
    JOURNAL OF PHARMACEUTICAL HEALTH CARE AND SCIENCES, 2024, 10 (01)
  • [4] Five years of safety profile of bevacizumab: an analysis of real-world pharmacovigilance and randomized clinical trials
    Li Wang
    Yibo Fei
    Han Qu
    Haiyang Zhang
    Yuanyuan Wang
    Zhenghua Wu
    Guorong Fan
    Journal of Pharmaceutical Health Care and Sciences, 10
  • [5] Sacubitril/Valsartan: From Clinical Trials to Real-world Experience
    Joly J.M.
    Desai A.S.
    Current Treatment Options in Cardiovascular Medicine, 2018, 20 (6)
  • [6] A REAL-WORLD PHARMACOVIGILANCE STUDY OF SACUBITRIL\VALSARTAN IN OLDER PEOPLE
    Kuai, Zheng
    Hu, Yu
    INNOVATION IN AGING, 2024, 8 : 132 - 132
  • [7] Safety Profile of Eltrombopag in Different Age Groups: An Analysis of Real-World Pharmacovigilance and Randomized Clinical Trials
    Qu, Han
    Wu, Jiaqi
    Ma, Cui
    Qiaolongbatu, Xijier
    Song, Xianmin
    Feng, Tingting
    Wu, Zhenghua
    Lou, Yuefen
    Fan, Guorong
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2023, 114 (01) : 201 - 210
  • [8] Updated insights on dementia-related risk of sacubitril/valsartan: A real-world pharmacovigilance analysis
    Chen, Congqin
    Ding, Lingqing
    Fu, Fang
    Xiao, Jie
    CNS NEUROSCIENCE & THERAPEUTICS, 2023, 29 (09) : 2548 - 2554
  • [9] Safety and effectiveness of Sacubitril-Valsartan in a real-world population
    Mariana Tinoco, M.
    Cardoso, F.
    Dias, G.
    Pereira, T.
    Faria, B.
    Almeida, F.
    Leite, S.
    Lourenco, A.
    EUROPEAN JOURNAL OF HEART FAILURE, 2022, 24 : 111 - 112
  • [10] The real-world safety of sacubitril / valsartan among older adults (≥75): A pharmacovigilance study from the FDA data
    Lerman, Tsahi T.
    Greenberg, Noam
    Fishman, Boris
    Goldman, Adam
    Talmor-Barkan, Yeela
    Bauer, Menachem
    Goldberg, Idan
    Goldberg, Elad
    Kornowski, Ran
    Krause, Ilan
    Levi, Amos
    Cohen, Eytan
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2024, 397
12345